Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose remifentanil for reversal of neuropathic pain in postherpetic neuralgia
2010-020042-94Phase 4Completed
- Sponsor
- Medical University of Vienna, University Clinic for Anesthesiology, General
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remifentanil in postherpetic neuralgia (PHN), sponsored by Medical University of Vienna, University Clinic for Anesthesiology, General. Primary endpoint: Primary: stimulus–response (S/R) function change in postherpetic hyperalgesia. Started Jul 2010; status: completed.
02
Drugs
remifentanil
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2010-020042-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020042-94.